T Cell Vaccines As An Immunotherapy For Type 1 Diabetes
School Name
The Center for Advanced Technical Studies
Grade Level
12th Grade
Presentation Topic
Cell and Molecular Biology
Presentation Type
Non-Mentored
Abstract
The goal of this project is to create a T cell vaccine which will reduce or eliminate circulating autoreactive CD4+ T cells in Type 1 Diabetes (T1D) patients. This vaccine will preserve the Honeymoon Phase, as well as lead to a cure for T1D when administered in conjunction with pancreatic islet transplantation. When T cell vaccines were studied in Multiple Sclerosis, all patients experienced a significant reduction in circulating autoreactive T cells, and all except one patient experienced no relapses. The T1D vaccine will be created by isolating CD4+ T cells from diabetic peripheral mononuclear blood cells, then attenuating proliferation and antigen expression in vitro with T Cell Protein Tyrosine Phosphatase. Patients who receive the vaccine are expected to experience a reduction in circulating autoreactive CD4+ T cells, while patients who receive the placebo are expected to experience no change in circulating autoreactive CD4+ T cells.
Recommended Citation
Morton, Emily, "T Cell Vaccines As An Immunotherapy For Type 1 Diabetes" (2015). South Carolina Junior Academy of Science. 187.
https://scholarexchange.furman.edu/scjas/2015/all/187
Start Date
4-11-2015 10:45 AM
End Date
4-11-2015 11:00 AM
T Cell Vaccines As An Immunotherapy For Type 1 Diabetes
The goal of this project is to create a T cell vaccine which will reduce or eliminate circulating autoreactive CD4+ T cells in Type 1 Diabetes (T1D) patients. This vaccine will preserve the Honeymoon Phase, as well as lead to a cure for T1D when administered in conjunction with pancreatic islet transplantation. When T cell vaccines were studied in Multiple Sclerosis, all patients experienced a significant reduction in circulating autoreactive T cells, and all except one patient experienced no relapses. The T1D vaccine will be created by isolating CD4+ T cells from diabetic peripheral mononuclear blood cells, then attenuating proliferation and antigen expression in vitro with T Cell Protein Tyrosine Phosphatase. Patients who receive the vaccine are expected to experience a reduction in circulating autoreactive CD4+ T cells, while patients who receive the placebo are expected to experience no change in circulating autoreactive CD4+ T cells.
